Can Psilocybin Help People Quit Smoking?
Yes. In this pilot clinical trial at Johns Hopkins, 40.5% of smokers who received a single dose of psilocybin achieved prolonged smoking abstinence at 6 months, compared to just 10% in the nicotine patch group. That means psilocybin gave participants more than six times greater odds of staying smoke-free.
Smoking remains one of the hardest addictions to break. Even with the best available treatments, most people who try to quit end up relapsing within months. Nicotine patches, gums, and prescription medications help some people, but success rates remain frustratingly low. This has pushed researchers to explore unconventional approaches, including psilocybin, the active compound found in certain mushrooms. A team at Johns Hopkins University designed a head-to-head trial to see how psilocybin stacks up against standard nicotine patch therapy for smoking cessation.
Dr. Kumar’s Take
I find these results genuinely exciting, even as a pilot study. A four-fold difference in quit rates is not something we see often in addiction medicine. What makes this even more interesting is that both groups received the same 13 weeks of cognitive behavioral therapy, so the difference really comes down to psilocybin versus the patch. The safety profile was also reassuring, with no serious adverse events in either group. That said, this was a relatively small trial with 82 participants, and we need larger, multi-site studies before psilocybin becomes a standard treatment. But as a signal of what might be possible, this is hard to ignore.
Study Snapshot
Researchers at Johns Hopkins randomized 82 adult smokers into two groups. One group received a single high dose of psilocybin (30 mg/70 kg body weight) in a supervised clinical setting. The other group received standard nicotine patch therapy. Both groups also participated in 13 weeks of cognitive behavioral therapy specifically designed for smoking cessation. This design was important because it isolated the effect of psilocybin versus the patch, since everyone got the same behavioral support. The primary outcome was prolonged smoking abstinence at 6 months, a rigorous measure that requires sustained quitting rather than just a single point of success.
Results in Context
The results were striking. At the 6-month mark, 40.5% of participants in the psilocybin group had achieved prolonged smoking abstinence. In the nicotine patch group, only 10% managed to stay smoke-free over that same period. This translates to more than six times greater odds of sustained abstinence for the psilocybin group. To put that in perspective, most FDA-approved smoking cessation treatments improve quit rates by about two to three times compared to placebo. A six-fold advantage, even in a small pilot, is a remarkable signal.
Safety was another encouraging finding. No serious adverse events were reported in either group during the study. This is consistent with growing evidence that psilocybin, when administered in a controlled clinical setting with proper screening and supervision, has a favorable safety profile.
Who Benefits Most
This study enrolled adult smokers who wanted to quit, so the findings apply broadly to motivated individuals struggling with nicotine addiction. The psilocybin session was conducted in a carefully controlled environment with trained facilitators, which is key. This is not about recreational use. The combination of a single powerful experience with weeks of structured therapy appears to be what drives the results. People who have tried and failed with standard treatments like patches, gums, or medications may find the most hope in these findings, though more research is needed to confirm which populations respond best.
Practical Takeaways
- Psilocybin-assisted therapy is still experimental and not yet approved for smoking cessation, so do not attempt this outside of a clinical trial or supervised medical setting.
- If you are trying to quit smoking, cognitive behavioral therapy remains a proven approach that helped both groups in this study and is widely available today.
- Talk to your doctor about all available options, including prescription medications like varenicline and bupropion, which have strong evidence for helping people quit.
- Watch for upcoming clinical trials if psilocybin-assisted therapy interests you, as several larger studies are now in progress at major research centers.
Related Studies and Research
- Single-dose psilocybin shows rapid, sustained antidepressant effects explores how a single psilocybin session can produce lasting changes in brain function and mood.
- Psilocybin-assisted therapy: Johns Hopkins trial shows major depression relief covers another landmark Johns Hopkins study on psilocybin for mental health.
- Single-dose psilocybin vs placebo: first double-blind depression trial examines the first placebo-controlled trial of psilocybin for depression.
- A randomized controlled trial of mindfulness-based cognitive therapy for major depressive disorder looks at how behavioral therapies can produce meaningful changes in brain health.
FAQs
How does psilocybin help people quit smoking?
Researchers believe psilocybin works differently from traditional cessation aids like nicotine patches. Instead of replacing nicotine, psilocybin appears to create a window of heightened psychological flexibility. During the supervised session, participants often report profound shifts in perspective about their relationship with smoking. This psychological “reset,” combined with weeks of cognitive behavioral therapy, may help break deeply ingrained habits in a way that nicotine replacement alone cannot. The exact brain mechanisms are still being studied, but early imaging research suggests psilocybin disrupts rigid patterns of thinking tied to addiction.
Is psilocybin therapy for smoking cessation available to the public?
Not yet. Psilocybin remains a Schedule I controlled substance in the United States, which means it cannot be legally prescribed outside of approved research studies. The FDA has granted “breakthrough therapy” designation to psilocybin for depression, which speeds up the review process, but no such designation exists yet specifically for smoking cessation. Several organizations are working to expand clinical trials, and some states like Oregon have created frameworks for supervised psilocybin use. However, it will likely be several years before psilocybin-assisted smoking cessation therapy becomes widely available through standard medical channels.
What made this study different from previous psilocybin smoking research?
Earlier research on psilocybin for smoking cessation used open-label designs, meaning everyone knew they were getting psilocybin, which makes it hard to separate the drug effect from the placebo effect. This Johns Hopkins trial was the first to use a randomized design comparing psilocybin directly against an active treatment (nicotine patches) rather than a placebo. Both groups also received the same cognitive behavioral therapy, which created a fair comparison. This stronger study design makes the six-fold difference in quit rates even more meaningful, though the researchers acknowledge that a larger trial with more participants is needed to confirm these promising results.
Bottom Line
This pilot trial from Johns Hopkins provides compelling early evidence that psilocybin-assisted therapy could be a powerful tool for smoking cessation. A single supervised psilocybin session, combined with cognitive behavioral therapy, helped four times as many smokers stay quit at 6 months compared to standard nicotine patch therapy. While larger trials are needed before this becomes a mainstream treatment, the six-fold advantage in abstinence odds and clean safety profile make a strong case for continued research into psychedelic-assisted approaches to addiction.
